Volume 141, Issue 2, Pages e4 (August 2011)

Slides:



Advertisements
Similar presentations
Pathogenic and Protective Roles of MyD88 in Leukocytes and Epithelial Cells in Mouse Models of Inflammatory Bowel Disease  Mark J. Asquith, Olivier Boulard,
Advertisements

Volume 138, Issue 2, Pages e3 (February 2010)
Volume 17, Issue 5, Pages (November 2002)
Volume 25, Issue 2, Pages (August 2006)
Volume 140, Issue 2, Pages e2 (February 2011)
Volume 133, Issue 5, Pages (November 2007)
Volume 133, Issue 4, Pages (October 2007)
Volume 143, Issue 5, Pages (November 2012)
Volume 136, Issue 4, Pages e3 (April 2009)
Volume 135, Issue 2, Pages e3 (August 2008)
Volume 133, Issue 6, Pages e14 (December 2007)
B Cells That Produce Immunoglobulin E Mediate Colitis in BALB/c Mice
Volume 136, Issue 3, Pages (March 2009)
Volume 138, Issue 4, Pages (April 2010)
Volume 131, Issue 4, Pages (October 2006)
Aryl Hydrocarbon Receptor Regulates Pancreatic IL-22 Production and Protects Mice From Acute Pancreatitis  Jing Xue, David T.C. Nguyen, Aida Habtezion 
Volume 143, Issue 5, Pages e4 (November 2012)
Volume 131, Issue 6, Pages (December 2006)
Volume 137, Issue 6, Pages e2 (December 2009)
Volume 134, Issue 2, Pages (February 2008)
Pathogenic and Protective Roles of MyD88 in Leukocytes and Epithelial Cells in Mouse Models of Inflammatory Bowel Disease  Mark J. Asquith, Olivier Boulard,
Volume 137, Issue 5, Pages e1 (November 2009)
Volume 141, Issue 5, Pages (November 2011)
Volume 144, Issue 5, Pages e6 (May 2013)
Volume 142, Issue 2, Pages e2 (February 2012)
Galectin-1 suppresses experimental colitis in mice
Volume 134, Issue 1, Pages e1 (January 2008)
Toll-Like Receptor 5 Engagement Modulates Tumor Development and Growth in a Mouse Xenograft Model of Human Colon Cancer  Sang Hoon Rhee, Eunok Im, Charalabos.
Volume 145, Issue 3, Pages e3 (September 2013)
Volume 141, Issue 4, Pages e1 (October 2011)
Volume 137, Issue 4, Pages (October 2009)
Volume 140, Issue 7, Pages (June 2011)
Volume 136, Issue 2, Pages (February 2009)
Volume 134, Issue 4, Pages e2 (April 2008)
Volume 139, Issue 6, Pages (December 2010)
Volume 138, Issue 2, Pages e3 (February 2010)
Volume 141, Issue 1, Pages e1 (July 2011)
Volume 143, Issue 3, Pages e2 (September 2012)
Volume 132, Issue 5, Pages (May 2007)
Volume 143, Issue 1, Pages (July 2012)
Volume 142, Issue 4, Pages e2 (April 2012)
Volume 138, Issue 2, Pages (February 2010)
Volume 132, Issue 1, Pages (January 2007)
This Month in Gastroenterology
Volume 128, Issue 3, Pages (March 2005)
Volume 134, Issue 7, Pages e3 (June 2008)
Volume 129, Issue 3, Pages (September 2005)
Therapeutic Action of Ghrelin in a Mouse Model of Colitis
Volume 146, Issue 7, Pages e4 (June 2014)
Volume 135, Issue 5, Pages e5 (November 2008)
Antigen-Presenting Cell Production of IL-10 Inhibits T-Helper 1 and 17 Cell Responses and Suppresses Colitis in Mice  Bo Liu, Susan L. Tonkonogy, R. Balfour.
Volume 135, Issue 2, Pages e2 (August 2008)
Volume 137, Issue 4, Pages (October 2009)
Ling Zheng, Terrence E. Riehl, William F. Stenson  Gastroenterology 
Mycobacterium bovis BCG killed by extended freeze-drying reduces airway hyperresponsiveness in 2 animal models  Micheline Lagranderie, PhD, Mohammad Abolhassani,
Leptin: A pivotal mediator of intestinal inflammation in mice
Volume 119, Issue 3, Pages (September 2000)
Volume 141, Issue 3, Pages (September 2011)
Volume 41, Issue 4, Pages (October 2014)
Helminth Infection Enhances Disease in a Murine TH2 Model of Colitis
CD8+ Cytotoxic T Cells Induce Relapsing Colitis in Normal Mice
Volume 132, Issue 2, Pages (February 2007)
CD4+ Lymphoid Tissue-Inducer Cells Promote Innate Immunity in the Gut
Volume 139, Issue 2, Pages (August 2010)
Colonic bacterial superantigens evoke an inflammatory response and exaggerate disease in mice recovering from colitis  Jun Lu, Arthur Wang, Sara Ansari,
Volume 131, Issue 2, Pages (August 2006)
Volume 17, Issue 5, Pages (October 2016)
Volume 136, Issue 7, Pages (June 2009)
Volume 131, Issue 6, Pages (December 2006)
Volume 137, Issue 6, Pages e2 (December 2009)
Presentation transcript:

Volume 141, Issue 2, Pages 642-652.e4 (August 2011) Mycobacterium bovis Bacillus Calmette-Guérin Killed by Extended Freeze-Drying Reduces Colitis in Mice  Micheline Lagranderie, Christoph Kluge, Helene Kiefer–Biasizzo, Mohammad Abolhassani, Marie–Anne Nahori, Catherine Fitting, Michel Huerre, Antonio Bandeira, Herve Bercovier, Gilles Marchal  Gastroenterology  Volume 141, Issue 2, Pages 642-652.e4 (August 2011) DOI: 10.1053/j.gastro.2011.05.002 Copyright © 2011 AGA Institute Terms and Conditions

Figure 1 Prophylactic EFD BCG treatment of C57Bl/6 mice reduced inflammation in acute DSS-induced colitis. (A) Body weight loss and clinical scores in PBS- and EFD BCG–treated mice. (B) Colon length and (C) representative H&E-stained colon sections showing inflammatory infiltrate and loss of normal architecture in PBS-treated mice and few inflammatory cells in EFD BCG–treated mice. Original magnification 4× (upper panel) and 10× (lower panel). (D) Foxp3 expression on gated CD4+ T cells from the spleen, MLNs, and lamina propria on day 5 (upper panel) and day 10 (lower panel) after DSS exposure. (E) Absolute number of CD4+Foxp3+ cells in the spleen, MLNs, and lamina propria on days 5 and 10. Data are representative of 2 independent experiments. n = 6 to 8 mice per group. *P < .05, **P < .01, ***P < .001. Gastroenterology 2011 141, 642-652.e4DOI: (10.1053/j.gastro.2011.05.002) Copyright © 2011 AGA Institute Terms and Conditions

Figure 2 Therapeutic EFD BCG treatment of C57Bl/6 mice reduced inflammation. (A and B) Body weight loss in acute and chronic model of DSS-induced colitis. (C) Inflammatory cytokines in spleen cell supernatants. (D) NF-κB and (E) PPAR-γ transcription factor levels determined in nuclear extracts of individual colon cells. Acute colitis, left panel; chronic colitis, right panel. n = 6 mice per group. *P < .05, ***P < .001. Gastroenterology 2011 141, 642-652.e4DOI: (10.1053/j.gastro.2011.05.002) Copyright © 2011 AGA Institute Terms and Conditions

Figure 3 Antibodies against TGF-β, IL-10, and CD25 blocked the protective effect of EFD BCG. Prophylactic EFD BCG treatment was administered in an acute model of DSS-induced colitis, and blocking antibodies and an isotype control were injected 2 days after the start of DSS treatment. (A) Body weight loss. (B) MPO activity expressed as arbitrary units per milligram of colon. (C) IL-10, TGF-β, and IL-17 levels in individual serum and (D) transcripts from 2 pools of 3 colons expressed as ratio versus GADPH. (E) Foxp3, T-bet, GATA-3, and RORγt expression in the spleen after injection of blocking antibodies. Transcription factors were analyzed by Western blotting and expressed as ratios of the normalized intensities of the bands (target proteins/β-actin). For each transcription factor, we analyzed 2 pools of spleen cell extracts from 3 mice. Black bars represent the isotype control. Data are representative of 2 independent experiments. n = 6 mice per group. **P < .01, ***P < .001. Gastroenterology 2011 141, 642-652.e4DOI: (10.1053/j.gastro.2011.05.002) Copyright © 2011 AGA Institute Terms and Conditions

Figure 4 Prophylactic EFD BCG treatment reduced Th2-type inflammation. (A) Weight loss measured from 8 days before oxazolone (OXA) sensitization to day 4 after intrarectal OXA challenge. (B) Colon length and distal lesions (insets) in PBS- and EFD BCG–treated mice. (C) Representative H&E-stained colon sections showing necrotic lesion with bleeding 4 days after OXA challenge in PBS-treated mice and only mild inflammation in EFD BCG–treated mice. Original magnification 10×, white arrow showing hemorrhage. (D) Cytokine levels in the individual serum. *P < .05, **P < .01, ***P < .001. Gastroenterology 2011 141, 642-652.e4DOI: (10.1053/j.gastro.2011.05.002) Copyright © 2011 AGA Institute Terms and Conditions

Figure 5 EFD BCG treatment at the time of naïve CD4+ T cells transfer to RAG2−/− mice reduced colitis features. Naïve CD4+CD45highFoxp3− (3 × 105) T cells were transferred to RAG2−/− mice at the time of PBS or EFD BCG treatment. (A) Body weight loss, (B) colon length, and MPO activity in the colon (arbitrary units/mg) were measured on day 50. (C) Representative H&E-stained colon sections showing inflammatory loss of normal architecture and ulceration in PBS-treated mice and few inflammatory cells in EFD BCG–treated mice. Original magnification 10×. (D) Cytokine levels in the individual serum. (E) NF-κB and PPAR-γ levels measured in individual colon cell extracts and RXRα phosphorylation measured by Western blotting in 2 pools of 3 colons. Data are representative of 2 independent experiments. n = 6 mice per group. *P < .05, **P < .01, ***P < .001. Gastroenterology 2011 141, 642-652.e4DOI: (10.1053/j.gastro.2011.05.002) Copyright © 2011 AGA Institute Terms and Conditions

Figure 6 EFD BCG treatment converted CD4+Foxp3− cells into CD4+Foxp3+ cells in RAG2−/− mice. (A) Fluorescence-activated cell sorter analysis of CD4+Foxp3 GFP+ spleen cells. (B) Foxp3 expression analyzed by Western blotting in spleen and colon extracts. (C) Transcription factors analyzed by Western blotting at day 50 in 2 pools of 3 spleen cell extracts and expressed as ratios of the normalized intensities of the bands (target proteins/β-actin). Data are representative of 2 independent experiments. n = 6 mice per group. Gastroenterology 2011 141, 642-652.e4DOI: (10.1053/j.gastro.2011.05.002) Copyright © 2011 AGA Institute Terms and Conditions

Supplementary Figure 1 Isotype control (rat immunoglobulin G2a). No significant positive cells stained with Foxp3 isotype control were found in the gate of CD4+Foxp3+ cells shown in Figure 1. Gastroenterology 2011 141, 642-652.e4DOI: (10.1053/j.gastro.2011.05.002) Copyright © 2011 AGA Institute Terms and Conditions

Supplementary Figure 2 EFD BCG treatment reduced the number of inflammatory cells in the gut in DSS-induced colitis. (A) Total number of cells and (B) absolute number of CD4+ T cells in the spleen, MLNs, and lamina propria 5 and 10 days after DSS treatment. n = 8 mice per group. *P < .05, **P < .01, ***P < .001 Gastroenterology 2011 141, 642-652.e4DOI: (10.1053/j.gastro.2011.05.002) Copyright © 2011 AGA Institute Terms and Conditions

Supplementary Figure 3 CD4+Foxp3+ cells isolated from EFD BCG–treated mice produced large amounts of IL-10. (A) Fluorescence-activated cell sorter analysis of cells producing IL-10 isolated 10 days after DSS treatment from the MLNs and lamina propria, and stimulated in vitro with PMA/ionomycin. (B) Absolute number of CD4+Foxp3+ cells producing IL-10. (C) Relative expression levels of IL-10 and TGF-β in Foxp3GFP+ cells isolated from MLNs of PBS- and EFD BCG–treated mice 10 days after DSS treatment. n= 5 to 8 mice per group. **P < .01, ***P < .001, Gastroenterology 2011 141, 642-652.e4DOI: (10.1053/j.gastro.2011.05.002) Copyright © 2011 AGA Institute Terms and Conditions

Supplementary Figure 4 EFD BCG treatment had no effect on the development of colon cancer. OF1 Swiss mice were treated with PBS or EFD BCG and were then submitted to 3 cycles of treatment with 5% DSS 21 days later. (A) Clinical scores after the last DSS cycle. (B) NF-κB and PPAR-γ transcription factor levels determined in nuclear extracts from individual colons. (C) Colon length and (D) indices of ulceration or erosion, polynuclear infiltration, and dysplasia. n = 25 mice per group. *P < .05, **P < .01, ***P < .001. Gastroenterology 2011 141, 642-652.e4DOI: (10.1053/j.gastro.2011.05.002) Copyright © 2011 AGA Institute Terms and Conditions